Oct 16, 2023 / 12:30PM GMT
Emil D. Kakkis - Ultragenyx Pharmaceutical Inc. - Founder, President, CEO & Director
Good morning, everyone. We're going to get started. It's great to see all of you here at the St. Regis and those of you online, beautiful day in New York City to be together and do a traditional Analyst Day.
We haven't done one for a while that we're an important inflection point for the company with so much going on. We thought it was an opportunity to really get you updated on all the pieces of what's happening with the company, which is what we'll do today. So on your sheet, you'll see an agenda on the table there.
And we'll basically -- I'll be starting with some opening remarks. We'll do a deep dive into UX143 for OI, a deep dive then into Angelman syndrome. And after a break, then we'll do a deep dive into our gene therapy franchise, including the Wilson and some initial data on Wilson for all of you. So I think it will be a very full day. I think a very exciting day because we'll have so much data coming out for you today, but also to tell a little bit about the company itself to get you
Ultragenyx Pharmaceutical Inc Present Pipeline Update at Analyst Day Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers